GHK-Cu Research Evidence: What the Published Studies Show for Skin, Wounds and Gene Data

GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. A PubMed search on 29 October 2026 for GHK-Cu, glycyl-histidyl-lysine, Gly-His-Lys or copper tripeptide returned 260 records, a number that includes some papers on the peptide without copper, and 16 of them list Loren Pickart as an author. Pickart is credited with isolating the peptide. A 2026 systematic review states that about 35% of the GHK-Cu primary literature in its inclusion window has Pickart or his colleague Anna Margolina of Skin Biology as an author, and notes his long commercial interest in the field.

That does not make the findings wrong, but it means independent confirmation is the thing to look for. This article goes through the cell, animal and human evidence and says where each piece comes from. It is a reading guide for researchers, not medical advice.

Cell studies: collagen and the extracellular matrix

The classic cell result is a 1988 paper from Maquart, Pickart and colleagues in FEBS Letters. GHK-Cu stimulated collagen synthesis by cultured fibroblasts. The stimulation began between 10^-12 and 10^-11 M, was maximal at 10^-9 M, and was independent of any change in cell number. The authors noted that a GHK sequence sits within the alpha-2 chain of type I collagen and suggested the tripeptide might be released by proteases at a wound. This is cell culture only.

Review articles by Pickart and co-authors in 2015 and 2018 summarise a broader set of effects: stimulation of blood vessel and nerve outgrowth, increased synthesis of collagen, elastin and glycosaminoglycans, and support of dermal fibroblast function. The 2015 review also states that the peptide can up- and down-regulate at least 4,000 human genes. These are the authors' own syntheses. Separate computational screens that queried the Connectivity Map database name Gly-His-Lys as a peptide predicted to reverse disease-related gene-expression signatures; those are database predictions about the peptide, not experiments with the copper complex.

Animal wound studies

A 2006 study in 18 New Zealand rabbits compared a copper tripeptide complex with zinc oxide and with no treatment on open wounds, and its authors concluded that the copper tripeptide was a better choice than zinc oxide in that model. The 2015 Pickart review also summarises accelerated wound healing in dogs, rats, mice and pigs. These findings are consistent with each other, but most of the underlying work again comes from a small number of groups.

Human studies: small, mostly cosmetic, and mixed

A 1992 randomised, evaluator-blinded trial in 86 evaluable patients with venous stasis ulcers compared 1% silver sulfadiazine, a 0.4% tripeptide copper complex cream and an inert vehicle. Silver sulfadiazine reduced ulcer size significantly more than either of the others, and there was no difference between the copper complex and the vehicle. The abstract does not name the complex as GHK-Cu, so treat the link as likely rather than certain.

A 2006 study of CO2 laser-resurfaced skin randomised patients to post-treatment skin care with or without GHK-Cu. Thirteen patients completed it. Blinded evaluators found no significant difference between groups in how fast redness resolved, and all patients improved in wrinkles and overall skin quality with no difference between groups. A validated questionnaire did show a significant difference in improvement of overall skin quality for the GHK-Cu users (P = .04).

Recent systematic reviews summarise the position. A 2026 review in Aesthetic Surgery Journal included 20 studies, 18 preclinical and 2 randomised trials, and reported that GHK-Cu improved patient-reported satisfaction after laser resurfacing and reduced wrinkle volume and depth against controls, while calling the evidence limited by methodological variability and few well-designed trials. Another 2026 systematic review described the human literature as thin and fragmented, with most randomised trials small and run on facial cosmetic creams. A 2025 review of topical GHK noted a surprising absence of clinical studies of GHK-Cu itself.

For injection there is no single-agent human trial in the abstracts we reviewed. The human injection reports involve multi-ingredient products, such as a scalp formulation that also contained several growth factors and thymosin beta-4 alongside copper tripeptide-1, so effects cannot be attributed to GHK-Cu. A 2026 narrative review in the American Journal of Sports Medicine concluded that GHK-Cu showed promise in wound healing and anti-inflammatory effects, but that no clinical data support its use for musculoskeletal conditions.

Irritation and copper: an in vitro finding

A 2016 study in cultured keratinocytes found that GHK-Cu was not cytotoxic and did not significantly change the expression of skin-irritation biomarkers, whereas simple copper salts at 58 and 580 micromolar raised several of them. The authors concluded that GHK-Cu has a low potential to cause irritation as a way of delivering copper. This is an in vitro result and says nothing about other routes or settings.

How to read this literature

Three points sum it up. The cell and animal evidence is consistent but concentrated in a few groups. The human evidence is small and mostly about topical cosmetic products, with one early ulcer trial that did not favour the copper complex. And claims about injectable use outrun the data. GHK-Cu is therefore best treated as a research compound with a coherent preclinical story and an unfinished clinical one.

QSC supplies GHK-Cu in 50 mg and 100 mg vials strictly for laboratory research; it is not approved for human or veterinary use, and nothing here is a dosing recommendation. Our companion article walks through reading a GHK-Cu certificate of analysis.

Sources

Maquart FX, Pickart L, Laurent M, Gillery P, Monboisse JC, Borel JP. Stimulation of collagen synthesis in fibroblast cultures by the tripeptide-copper complex glycyl-L-histidyl-L-lysine-Cu2+. FEBS Letters, 1988;238(2):343-346. doi:10.1016/0014-5793(88)80509-x. PMID 3169264.

Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. BioMed Research International, 2015;2015:648108. doi:10.1155/2015/648108. PMID 26236730. Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences, 2018;19(7):1987. doi:10.3390/ijms19071987. PMID 29986520.

Hong Y et al. Connectivity Map analysis naming Gly-His-Lys, 2010. PMID 20143136. Zhao Q et al., 2019. PMID 31545431.

Cangul IT et al. Veterinary Dermatology, 2006 (copper tripeptide complex in open wounds of rabbits). PMID 17083573.

Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for the treatment of venous stasis ulcers. Journal of Vascular Surgery, 1992;16(2):251-257. doi:10.1067/mva.1992.37086. PMID 1495150.

Miller TR et al. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Archives of Facial Plastic Surgery, 2006;8(4):252-259. doi:10.1001/archfaci.8.4.252. PMID 16847171.

Mokhtar J et al. The regenerative potential of GHK-Cu in aesthetic medicine. Aesthetic Surgery Journal, 2026 (online ahead of print, 20 August 2026). doi:10.1093/asj/sjag169. PMID 42619529.

Najafi N et al. A systematic review of the mechanisms and therapeutic applications of GHK-Cu in topical microneedle delivery: a case for expanded clinical trials. Archives of Internal Medicine Research, 2026;9(3):269-293. doi:10.26502/aimr.0255. PMID 42787770.

Mortazavi SM et al. Topically applied GHK as an anti-wrinkle peptide: advantages, problems and prospective. BioImpacts, 2025;15:30071. doi:10.34172/bi.30071. PMID 39963574.

Kapoor R, Shome D. Journal of Cosmetic and Laser Therapy, 2018 (open-label pilot of an intradermal multi-ingredient scalp formulation). PMID 29482481. Mayfield CK et al. Injectable peptide therapy: a primer for orthopaedic and sports medicine physicians. American Journal of Sports Medicine, 2026;54(1):223-229. doi:10.1177/03635465251357593. PMID 41476424.

Li H et al. Scientific Reports, 2016 (GHK-Cu and skin irritation biomarkers in keratinocytes). doi:10.1038/srep37664. PMID 27892491.

PubMed record counts: query (GHK-Cu OR "glycyl-histidyl-lysine" OR "Gly-His-Lys" OR "copper tripeptide"), run 29 October 2026; the term also returns some records on the peptide without copper.